Treating moderate to severe psoriasis – best use of biologics

References

• Parisi R, Symmons DP, Griffiths CE, Ashcroft DM; Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) Project Team. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 2013;133(2):377-85
   PubMed Web of Science ®Google Scholar
• Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet 2007;370(9583):263-71
   PubMed Web of Science ®Google Scholar
• Neimann AL, Shin DB, Wang X, et al. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006;55(5):829-35
   PubMed Web of Science ®Google Scholar
• Haroon M, Kirby B, Fitzgerald O. High prevalence of psoriatic arthritis in patients with severe psoriasis with suboptimal performance of screening questionnaires. Ann Rheum Dis 2013;72(5):736-40
   PubMed Web of Science ®Google Scholar
• Gelfand JM, Troxel AB, Lewis JD, et al. The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol 2007;143(12):1493-9
   PubMed Web of Science ®Google Scholar
• Nast A, Reytan N, Rosumeck S, et al. Low prescription rate for systemic treatments in the management of severe psoriasis vulgaris and psoriatic arthritis in dermatological practices in Berlin and Brandenburg, Germany: results from a patient registry. J Eur Acad Dermatol Venereol 2008;22(11):1337-42
   PubMed Web of Science ®Google Scholar
• NICE. Available from: www.nice.org.uk/usingguidance/commissioningguides/biologicaltherapies/CommissioningBiologicDrugs.jsp [Last accessed 11 September 2013]
   Google Scholar
• Staidle JP, Dabade TS, Feldman SR. A pharmacoeconomic analysis of severe psoriasis therapy: a review of treatment choices and cost efficiency. Expert Opin Pharmacother 2011;12(13):2041-54
   PubMed Web of Science ®Google Scholar
• Fonia A, Jackson K, Lereun C, et al. A retrospective cohort study of the impact of biologic therapy initiation on medical resource use and costs in patients with moderate to severe psoriasis. Br J Dermatol 2010;163(4):807-16
   PubMed Web of Science ®Google Scholar
• Warren RB, Brown BC, Lavery D, et al. Biologic therapies for psoriasis: practical experience in a U.K. tertiary referral centre. Br J Dermatol 2009;160(1):162-9
   PubMed Web of Science ®Google Scholar
• Driessen RJ, Bisschops LA, Adang EM, et al. The economic impact of high-need psoriasis in daily clinical practice before and after the introduction of biologics. Br J Dermatol 2010;162(6):1324-9
   PubMed Web of Science ®Google Scholar
• Nast A, Boehncke WH, Mrowietz U, et al. S3 - guidelines on the treatment of psoriasis vulgaris (English version). J Dtsch Dermatol Ges 2012;10(Suppl 2):S1-S95
   Web of Science ®Google Scholar
• NICE. Available from: www.nice.org.uk/nicemedia/live/13938/61192/61192.pdf Last accessed 11 September 2013 ]
   Google Scholar
• Smith CH, Anstey AV, Barker JNWN, et al. British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. Br J Dermatol 2009;161(5):987-1019
   PubMed Web of Science ®Google Scholar
• Pathirana D, Ormerod AD, Saiag P, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009;23(Suppl 2):1-70
   PubMed Web of Science ®Google Scholar
• Nast A, Sporbeck B, Rosumeck S, et al. Which antipsoriatic drug has the fastest onset of action? – Systematic review on the rapidity of the onset of action. J Invest Dermatol 2013;133(8):1963-70
   PubMed Web of Science ®Google Scholar
• Noiles K, Vender R. Biologic Survival. J Drugs Dermatol 2009;8(4):329-33
   PubMed Web of Science ®Google Scholar
• Gniadecki R, Kragballe K, Dam TN, Skov L. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris. Br J Dermatol 2011;164(5):1091-6
   PubMed Web of Science ®Google Scholar
• Esposito M, Gisondi P, Cassano N, et al. Survival rate of antitumour necrosis factor-alpha treatments for psoriasis in routine dermatological practice: a multicentre observational study. Br J Dermatol 2013;169(3):666-72
   PubMed Web of Science ®Google Scholar
• van den Reek JM, van Lumig PP, Driessen RJ, et al. Determinants of drug-survival of etanercept for psoriasis in a long-term daily practice cohort. Br J Dermatol 2013; Epub ahead of print
   Google Scholar
• Enbrel® (etanercept) Summary of Product Characteristics (SPC). Pfizer Limited, electronic medicines compendium, Kent, UK; 2013
   Google Scholar
• Paller AS, Siegfried EC, Langley RG, et al. Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med 2008;358(3):241-51
   PubMed Web of Science ®Google Scholar
• Gordon K, Papp K, Poulin Y, et al. Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL. J Am Acad Dermatol 2012;66(2):241-51
   PubMed Web of Science ®Google Scholar
• Jani M, Barton A, Warren RB, et al. The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases. Rheumatology 2013; Epub ahead of print
   Web of Science ®Google Scholar
• Barker J, Hoffmann M, Wozel G, et al. Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1). Br J Dermatol 2011;165(5):1109-17
   PubMed Web of Science ®Google Scholar
• Reich K, Wozel G, Zheng H, et al. Efficacy and safety of infliximab as continuous or intermittent therapy in patients with moderate-to-severe plaque psoriasis: results of a randomized, long-term extension trial (RESTORE2). Br J Dermatol 2013;168(6):1325-34
   PubMed Web of Science ®Google Scholar
• Papoutsaki M, Talamonti M, Giunta A, et al. The impact of methodological approaches for presenting long-term clinical data on estimates of efficacy in psoriasis illustrated by three-year treatment data on infliximab. Dermatology 2010;221(Suppl 1):43-7
   PubMed Web of Science ®Google Scholar
• Kimball AB, Papp KA, Wasfi Y, et al. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study. J Eur Acad Dermatol Venereol 2012; Epub ahead of print
   Google Scholar
• Stelara^® (ustekinumab) Summary of Product Characteristics (SPC). Janssen-Cilag Limited, electronic medicines compendium, Bucks, UK; 2013
   Google Scholar
• Laws PM, Downs AM, Parslew R, et al. Practical experience of ustekinumab in the treatment of psoriasis: experience from a multicentre, retrospective case cohort study across the U.K. and Ireland. Br J Dermatol 2012;166(1):189-95
   PubMed Web of Science ®Google Scholar
• Saurat JH, Stingl G, Dubertret L, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008;158(3):558-66
   PubMed Web of Science ®Google Scholar
• Griffiths CE, Strober BE, van de Kerkhof P, et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010;362(2):118-28
   PubMed Web of Science ®Google Scholar
• Warren RB, Brown BC, Lavery D, Griffiths CE. Adalimumab for psoriasis: practical experience in a U.K. tertiary referral centre. Br J Dermatol 2010;163(4):859-62
   PubMed Web of Science ®Google Scholar
• Ryan C, Kirby B, Collins P, Rogers S. Adalimumab treatment for severe recalcitrant chronic plaque psoriasis. Clin Exp Dermatol 2009;34(7):784-8
   PubMed Web of Science ®Google Scholar
• Remicade^® (infliximab) Summary of Product Characteristics (SPC). Merck Sharp & Dohme Limited, electronic medicines compendium, Hertfordshire, UK; 2013
   Google Scholar
• Humira® (adalimumab) Summary of Product Characteristics (SPC). AbbVie Limited, electronic medicines compendium, Maidenhead, UK; 2013
   Google Scholar
• Mahil SK, Arkir Z, Richards G, et al. Predicting treatment response in psoriasis using serum levels of adalimumab and etanercept: a single-centre, cohort study. Br J Dermatol 2013;169(2):306-13
   PubMed Web of Science ®Google Scholar
• Cozanni E, Burlando M, Parodi A. Detection of antibodies to anti-TNF agents in psoriatic patients: a preliminary study. G Ital Dermatol Venereol 2013;148(2):171-4
   PubMed Web of Science ®Google Scholar
• Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007;66(7):921-6
   PubMed Web of Science ®Google Scholar
• Leman J, Burden AD. Sequential use of biologics in the treatment of moderate-to-severe plaque psoriasis. Br J Dermatol 2012;167(Suppl 3):12-20
   PubMed Web of Science ®Google Scholar
• Ormerod AD, Augustin M, Baker C, et al. Challenges for synthesising data in a network of registries for systemic psoriasis therapies. Dermatology 2012;224(3):236-43
   PubMed Web of Science ®Google Scholar
• Rustin MH. Long-term safety of biologics in the treatment of moderate-to-severe plaque psoriasis: review of current data. Br J Dermatol 2012;167(Suppl 3):3-11
   PubMed Web of Science ®Google Scholar
• Leonardi C, Papp K, Strober B, et al. The long-term safety of adalimumab treatment in moderate to severe psoriasis: a comprehensive analysis of all adalimumab exposure in all clinical trials. Am J Clin Dermatol 2011;12(5):321-37
   PubMed Web of Science ®Google Scholar
• Burmester GR, Panaccione R, Gordon KB, et al. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Ann Rheum Dis 2013;72(4):517-24
   PubMed Web of Science ®Google Scholar
• Ryan C, Leonardi CL, Krueger JG, et al. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA 2011;306(8):864-71
   PubMed Web of Science ®Google Scholar
• Mrowietz U, de Jong EM, Kragballe K, et al. A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol 2013; Epub ahead of print
   Web of Science ®Google Scholar
• Philipp S, Wilsmann-Theis D, Weyergraf A, et al. Combination of adalimumab with traditional systemic antipsoriatic drugs - a report of 39 cases. J Dtsch Dermatol Ges 2012;10(11):821-37
   PubMed Web of Science ®Google Scholar
• Heinecke GM, Luber AJ, Levitt JO, Lebwohl MG. Combination use of ustekinumab with other systemic therapies: a retrospective study in a tertiary referral center. J Drugs Dermatol 2013;12(10):1098-102
   PubMed Web of Science ®Google Scholar
• Puig L, Carrascosa JM, Carratero G, et al. Spanish evidence-based guidelines on the treatment of psoriasis with biologic agents, 2013. Part 1: on efficacy and choice of treatment. Actas Dermosifiliogr 2013;104(8):694-709
   PubMedGoogle Scholar
• Heller MM, Wu JJ, Murase JE. Fatal case of disseminated BCG infection after vaccination of an infant with in utero exposure to infliximab. J Am Acad Dermatol 2011;65(4):870
   PubMed Web of Science ®Google Scholar
• Ostensen M, Forger F. How safe are anti-rheumatic drugs during pregnancy? Curr Opin Pharmacol 2013;13(3):470-5
   PubMed Web of Science ®Google Scholar
• Chambers CD, Johnson DL. Emerging data on the use of anti-tumor necrosis factor-alpha medications in pregnancy. Birth Defects Res A Clin Mol Teratol 2012;94(8):607-11
   PubMed Web of Science ®Google Scholar
• Carter JD, Ladhani A, Ricca L, et al. A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the Food and Drug Administration database. J Rheumatol 2009;36(3):635-41
   PubMed Web of Science ®Google Scholar
• Koren G, Inoue M. Do tumor necrosis factor inhibitors cause malformations in humans? J Rheumatol 2009;36(3):465-6
   PubMed Web of Science ®Google Scholar
• Hession MT, Gottlieb AB. Perioperative management of tumor necrosis factor antagonists in patients with psoriasis and other inflammatory disorders. J Dermatolog Treat 2011;22(2):90-101
   PubMed Web of Science ®Google Scholar
• Leonardi C, Matheson R, Zachariae C, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 2012;366(13):1190-9
   PubMed Web of Science ®Google Scholar
• Papp KA, Leonardi C, Menter A, et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med 2012;366(13):1181-9
   PubMed Web of Science ®Google Scholar
• Papp KA, Langley RG, Sigurgeirsson B, et al. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled Phase II dose-ranging study. Br J Dermatol 2013;168(2):412-21
   PubMed Web of Science ®Google Scholar
• Rich P, Sigurgeirsson B, Thaci D, et al. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, Phase II regimen-finding study. Br J Dermatol 2013;168(2):402-11
   PubMed Web of Science ®Google Scholar
• Novartis. Available from: www.novartis.com/newsroom/media-releases/en/2013/1733280.shtml
   Google Scholar
• Rheumatology news. Available from: www.rheumatologynews.com/single-view/secukinumab-soars-in-Phase-iii-psoriasis-studies/8f38c056a29d20b046dd5793653bfaa1.html?tx_ttnews%5BsViewPointer%5D=1
   Google Scholar
• Internal medicine news. Available from: www.internalmedicinenews.com/index.php?id=2049&type=98&tx_ttnews%5Btt_news%5D=220009&cHash=da03e20e36
   Google Scholar
• Chiricozzi A, Krueger JG. IL-17 targeted therapies for psoriasis. Expert Opin Investig Drugs 2013;22(8):993-1005
   PubMed Web of Science ®Google Scholar
• Huppler AR, Bishu S, Gaffen SL. Mucocutaneous candidiasis: the IL-17 pathway and implications for targeted immunotherapy. Arthritis Res Ther 2012;14(4):217
   PubMed Web of Science ®Google Scholar
• Sabat R, Wolk K. Research in practice: IL-22 and IL-20: significance for epithelial homeostasis and psoriasis pathogenesis. J Dtsch Dermatol Ges 2011;9(7):518-23
   PubMed Web of Science ®Google Scholar
• Wolk K, Haugen HS, Xu W, et al. IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-gamma are not. J Mol Med 2009;87(5):523-36
   PubMed Web of Science ®Google Scholar
• Papp KA, Menter A, Strober B, et al. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase IIb randomized placebo-controlled dose-ranging study. Br J Dermatol 2012;167(3):668-77
   PubMed Web of Science ®Google Scholar
• Ports WC, Khan S, Lan S, et al. A randomized Phase IIa efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis. Br J Dermatol 2013;169(1):137-45
   PubMed Web of Science ®Google Scholar
• Palfreeman AC, McNamee KE, McCann FE. New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast. Drug Des Devel Ther 2013;7:201-10
   PubMed Web of Science ®Google Scholar
• Papp KA, Kaufmann R, Thaci D, et al. Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a Phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study. J Eur Acad Dermatol Venereol 2012; Epub ahead of print
   Google Scholar
• Papp K, Cather JC, Rosoph L, et al. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial. Lancet 2012;380(9843):738-46
   PubMed Web of Science ®Google Scholar
• Burden AD, Warren RB, Kleyn CE, et al. The British Association of Dermatologists' Biologic Interventions Register (BADBIR): design, methodology and objectives. Br J Dermatol 2012;166(3):455-4
   PubMed Web of Science ®Google Scholar
• Ryan C, Menter A, Warren RB. The latest advances in pharmacogenetics and pharmacogenomics in the treatment of psoriasis. Mol Diagn Ther 2010;14:81-93
   PubMed Web of Science ®Google Scholar
• Strober BE, Armour K, Romiti R, et al. Biopharmaceuticals and biosimilars in psoriasis: what the dermatologist needs to know. J Am Acad Dermatol 2012;66(2):317-22
   PubMed Web of Science ®Google Scholar
• Leng RX, Pan HF, Tao JH, Ye DQ. IL-19, IL-20 and IL-24: potential therapeutic targets for autoimmune diseases. Expert Opin Ther Targets 2011;15(2):119-26
   PubMed Web of Science ®Google Scholar